Our goal is to continue to advance the successful, multidisciplinary research agenda of the Antibacterial Resistance Leadership Group (ARLG). In the original award period, the ARLG agenda increased scientific knowledge of antibacterial resistance and sought to mitigate important factors that drive its expansion. We continue to pair an unprecedented team of over two dozen of the world's top investigators with the organizational excellence of the Duke Clinical Research Institute (DCRI), one of the world's largest Academic Research Organizations. Because of the complexity of integrating multiple components of such a large-scale clinical research network, our renewal continues to feature centralized leadership through an Executive Committee and a dual PI approach. One PI (Fowler) focuses primarily on operations and the other (Chambers) focuses largely on scientific agenda. The organizational structure also features Scientific Subcommittees devoted to three priority areas: Gram-negative bacterial infections, Gram-positive bacterial infections, and Diagnostics. These Subcommittees are supported by internationally recognized Collaborating Investigators to advance four core value areas: 1) Scientific Expertise; 2) Innovations; 3) Mentoring and Diversity; and 4) Network Development. To complement the ongoing research activities of both the diagnostic and the pharmaceutical industries, our ARLG has established collaborative ties with members of both communities. Our long-term research goal is to improve outcomes of multiple-drug resistant (MDR) bacterial infections by designing and conducting transformational diagnostic and therapeutic clinical trials. Our research portfolio will pursue this goal in therapeutics by conducting first-in kind strategy trials in MDR Gram-negative bacteria and MRSA and by studying nontraditional therapeutics (monoclonal antibodies and bacteriophages) against MDR Pseudomonas aeruginosa. We will pursue this goal in diagnostics by obtaining FDA approval for a host gene expression-based diagnostic and by evaluating the clinical impact of rapid phenotypic testing in patients with bloodstream infection. Our research agenda reflects a realistic strategy of incremental steps towards complex practice-changing trials.
Our Specific Aims are to 1) To maintain a Scientific Leadership Center (SLC) that provides overall scientific and administrative leadership for the network; 2) To maintain a Clinical Operations Center (COC) that provides operational support, management, and oversight for the network?s clinical studies and trials; 3) To maintain a Laboratory Center (LC) that advances the ARLG research agenda by leading the development, implementation, and evaluation of essential laboratory research; and 4): To maintain a Statistics and Data Management Center (SDMC) that advances the ARLG research agenda by providing leadership in biostatistics, study design, analysis, interpretation, and publication of results. By advancing these specific aims, our renewal will build upon the productivity and innovation assembled in our original award to advance the ARLG scientific agenda against one of the leading threats to human health.
Antibacterial resistance (AR) is one of the world?s top health threats. It is a complex, growing problem. Reducing the burden of AR requires a sustained program that simultaneously addresses critical issues from many perspectives. Our goal is to continue to advance our success of the Antibacterial Resistance Leadership Group (ARLG) that has developed, designed, implemented, and managed a clinical research agenda that increases knowledge of AR, and reduces the factors that drive its emergence.
|Bassetti, Matteo; Righi, Elda; Montravers, Philippe et al. (2018) What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. J Antimicrob Chemother 73:i14-i25|
|van Duin, David; Lok, Judith J; Earley, Michelle et al. (2018) Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis 66:163-171|
|Wenzler, Eric; Bleasdale, Susan C; Sikka, Monica et al. (2018) Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. Antimicrob Agents Chemother 62:|
|Chotiprasitsakul, Darunee; Han, Jennifer H; Cosgrove, Sara E et al. (2018) Comparing the Outcomes of Adults With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort. Clin Infect Dis 66:172-177|
|Robinson, Matthew L; Kadam, Dileep; Kagal, Anju et al. (2018) Antibiotic Utilization and the Role of Suspected and Diagnosed Mosquito-borne Illness Among Adults and Children With Acute Febrile Illness in Pune, India. Clin Infect Dis 66:1602-1609|
|Miller, William R; Seas, Carlos; Carvajal, Lina P et al. (2018) The Cefazolin Inoculum Effect Is Associated With Increased Mortality in Methicillin-Susceptible Staphylococcus aureus Bacteremia. Open Forum Infect Dis 5:ofy123|
|Hamasaki, Toshimitsu; Evans, Scott R; Asakura, Koko (2018) Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review. J Biopharm Stat 28:28-51|
|Richter, Sandra S; Karichu, James; Otiso, Joshua et al. (2018) Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant Klebsiella pneumoniae to polymyxins. Diagn Microbiol Infect Dis 91:89-92|
|Mamo, Yafet; Woodworth, Michael H; Wang, Tiffany et al. (2018) Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis 66:1705-1711|
|van Duin, David; Gu, Peidi; Dong, Jane et al. (2018) China-United States Research Collaborations in Antimicrobial Resistance. Clin Infect Dis 67:S142-S145|
Showing the most recent 10 out of 119 publications